Ephedrine hydrochloride 15mg / Chlorphenamine 10mg tablets
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Yellow Card
Report side effects (MHRA)
Drug safety updates
MHRA alerts for Ephedrine + Chlorphenamine
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Browse all Drug Analysis Profiles A–Z
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
Search EudraVigilance database
Browse substances A–Z in the European adverse reaction database
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
1 branded products available
NHS prescribing volume and spending trends
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0.
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
1954–2026
Showing the 50 most relevant studies, sorted by most relevant.
S. A. Piletsky, K. Karim, E. V. Piletska, et al.
The Analyst, 2001
Andrew S. Thompson, Edward G. Corley, Martha F. Huntington, et al.
Tetrahedron Letters, 1995
Sandeep S Vansal, Dennis R Feller
Biochemical Pharmacology, 1999
Douglas G. Bell, Ira Jacobs, Jiri Zamecnik
European Journal of Applied Physiology, 1998
B.J. Gurley, P. Wang, S.F. Gardner
Journal of Pharmaceutical Sciences, 1998
Lin J, Liu Z, Guan T, et al.
2024
Chlorphenamine maleate is a prohibited additive found in herbal teas and health foods. Excessive intake of this substance can result in adverse health effects. In this study, two novel haptens, PEM and bepotastine (PB1), mimicking chlorphenamine maleate structure were designed and synthesized based on molecular simulation for developing two corresponding polyclonal antibodies (PEM-Ab and PB1-Ab), respectively. Afterward, an indirect competitive enzyme-linked immunosorbent assay (ic-ELISA) was developed to quickly and accurately detect chlorphenamine maleate in herbal teas using PB1-Ab, which has a high sensitivity and specificity. For chlorphenamine maleate, the half-maximal inhibitory concentration (IC50) and limit of detection (LOD) of PB1-Ab under ideal circumstances were found to be 1.18 µg/L and 0.07 µg/L, respectively. Besides, an environmentally friendly sample pre-treatment strategy was employed that allowed easy and effective elimination of complex matrices. The ic-ELISA method observed the average recovery rate from 87.7% to 94.0% with the variance coefficient (CV) ranging from 2.2% to 9.4%. Additionally, the identification of 25 commercially available herbal teas using liquid chromatography-tandem mass spectrometry (LC-MS/MS) further confirmed the validity of our detection. The results of the two methods are consistent. Overall, the proposed ic-ELISA could be an ultrasensitive and reliable method for chlorphenamine maleate adulterated in foods or exposure to the environment.
Abstract licence: CC BY
W. Roy Jackson, Howard A. Jacobs, Barry R. Matthews, et al.
Tetrahedron Letters, 1990
Şener H, Yavuz Güzel E, Karakuş H
2026
- Water Pollutants, Chemical
- Hot Springs
- Personal Care Products
The increasing global consumption of pharmaceuticals and personal care products (PPCPs) and their persistence in the environment have raised concerns about their potential ecological and human health risks, especially in aquatic systems. Thermal waters, widely used for therapeutic and agricultural purposes, remain underexplored regarding PPCP contamination. This study presents a comprehensive environmental risk assessment (ERA) of 104 PPCPs in thermal waters from 22 sampling points across nine geothermal fields in Kütahya, Türkiye. A total of five PPCPs (caffeine, DEET, ephedrine, carbamazepine, and chlorphenamine) were quantified using a validated LC-MS/MS method. Caffeine exhibited the highest detection frequency (100%) and maximum concentration (43.191 ng L-1), followed by DEET (90.9%) and ephedrine (77.2%). Risk quotients (RQs) were calculated based on predicted no-effect concentrations (PNECs) derived from ECOSAR v2.2, and the mixture risk quotient (MRQ) approach was applied to assess the cumulative ecological risks of PPCP mixtures. The results indicate that although most individual compounds pose low to medium ecological risk levels (RQ 1) in several locations, suggesting potential chronic threats, especially to algae and invertebrates. No significant correlation emerged between PPCP levels and water parameters, indicating their persistence. Geological and hydrogeological factors, such as fault-controlled mixing between shallow and deep aquifers, were identified as pathways for contamination. These findings highlight the need for regulatory oversight of PPCPs in thermal waters and recommend safeguards, such as isolating well intakes from shallow aquifers, to reduce ecological and health risks.
Abstract licence: CC BY
Penny A. Chaloner, S.A.Renuka Perera
Tetrahedron Letters, 1987
D Molnár, K Török, E Erhardt, et al.
International Journal of Obesity, 2000
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Scientific data (pharmacology, interactions, ADME) is not yet available for this medicine. Clinical sections are sourced from the NHS dm+d database.